PT 3
Alternative Names: PT-3; PT3 - Imagine PharmaLatest Information Update: 22 Oct 2024
At a glance
- Originator Imagine Pharma
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 22 Oct 2024 Phase-I clinical trials in Type 2 diabetes mellitus (PO), prior to October 2024 (Imagine Pharma pipeline, October 2024)
- 31 Oct 2023 Imagine pharma plans a phase I trial for Type 2 diabetes mellitus in USA in 2024 (PO) (Imagine Pharma pipeline, November 2023)
- 31 Oct 2023 PT 3 is available for licensing as of 31 Oct 2023. https://imaginepharma.com/programs/#pt-1